When injected into mice with retinal disease, the special retinal blood cells integrated into the damaged tissue to ...

Organ fragments grown in the laboratory will accelerate the testing of gene therapy methods for visual pathologies ...

Sports Chosun Jang Jong-ho] The development of a gene therapy for inherited retinal diseases is drawing closer.

Life Biosciences has received FDA clearance to begin a first-in-human Phase 1 clinical trial of ER-100, a gene therapy ...

Successful Type B RDEP Meeting confirms FDA alignment on pivotal Phase 3 study designFDA indicates Opus Genetics may submit a BLA based on ...

Ocugen has no product revenue, remains loss-making, and the convertible notes add debt burden and potential share dilution.

To circumvent the unreliability of animal models, which often fail to mirror human retinal biology due to vast physiological disparities, Russian researchers have successfully cultivated living ...

Estimated global prevalence is 21,800 patients, including 8,400 patients in the U.S. comprised of approximately 8,000 best vitelliform macular dystrophy (BVMD) and approximately 400 autosomal ...

Quantified preferences favored higher lesion growth rate reduction (10%→50% at 18 months) as the primary driver across all ...

From data lakes to streamlined production, Kriya, Opus, and Epicrispr discuss how technology is improving their operations.

The Foundation Fighting Blindness and its venture arm, the RD Fund (Retinal Degeneration Fund), today announced a $1 million commitment from A Race Against Blindness (RAB) to advance gene-agnostic ...

Belite Bio, Inc (NASDAQ: BLTE) ('Belite Bio®” or the 'Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have ...